Study Evaluating Rapamune in Patients After Kidney Transplantation

An Open Label Post Marketing Surveillance Assessment to Evaluate the Effectiveness and Safety of Rapamune in Patients After Kidney Transplantation Receiving a Rapamune Containing Regime

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00240214

Enrollment

500

Registered

2005-10-17

Start date

2001-04-30

Completion date

2008-02-29

Last updated

2008-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Transplantation

Keywords

Kidney transplants

Brief summary

The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions

Interventions

DRUGsirolimus

Tablet, dosage is determined by trough level

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients having received a renal allograft from a cadaveric or living donor with low or moderate risk of developing acute rejection episodes.

Exclusion criteria

* Contraindications according to Summary of the Product Characteristics (SmPC).

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026